ARCH Venture Partners IX, LLC bought 2,321,262 shares of Lyell Immunopharma, Inc. at $10.77 for $25.0M on Nov 4, 2026

Buy
Form 4 code P. Open-market or private purchase of a non-derivative or derivative security.
10% owner
10%
Filed Nov 5, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
$24,999,991.74Shares × reported price
Shares traded
2,321,262Common Stock
Price per share
$10.77Reported price. Read footnotes for ranges.
% of reported position traded
162.72%This security and ownership context
Holdings after
3,747,790Indirect · See Footnote
Trade date
Nov 4, 2026Buy
Filed
Nov 5, 2026, 5:35 PM ET1-day reporting delay
Accession
0001012975-26-001014Code P · Transaction 393882
How reported position traded is calculated

Shares purchased ÷ (holdings after − shares purchased). Estimated position before: 1,426,528 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

No other transaction rows in this filing.

1 transaction row in this filing. Joint filers share the same rows.

LYEL price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
LYEL · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago −40%1w ago −27%1d ago −28%
Returns since7d +4.3%30d90d180d1y

Footnotes in full

F1: These shares were purchased on November 4, 2026 pursuant to a securities purchase agreement dated November 3, 2026 at a price per share of $10.77. F2: These shares are directly held by ARCH Venture Fund XIII, L.P. ("ARCH XIII"). ARCH Venture Partners XIII, L.P. ("AVP XIII LP") is the general partner of ARCH XIII. ARCH Venture Partners XIII, LLC ("AVP XIII LLC") is the general partner of AVP XIII LP. Keith Crandell, Robert Nelsen, Kristina Burow, Paul Berns and Steven Gillis are members of the investment committee of AVP XIII LLC (the "AVP XIII LLC Committee Members"). Each of AVP XIII LP and AVP XIII LLC may be deemed to beneficially own the shares held by ARCH XIII, and each of the AVP XIII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XIII. Each of AVP XIII LP, AVP XIII LLC and the AVP XIII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any. F3: These shares are directly held by ARCH Venture Fund IX, L.P. ("ARCH IX"). ARCH Venture Partners IX, L.P. ("GPLP"), as the sole general partner of ARCH IX, may be deemed to beneficially own the shares held by ARCH IX. ARCH Venture Partners IX, LLC ("GPLLC"), as the sole general partner of GPLP, may be deemed to beneficially own the shares held by ARCH IX. As managing directors of GPLLC, each of Keith Crandell, Robert Nelsen and Clinton Bybee (the "ARCH Managing Directors"), may be deemed to beneficially own the shares held by ARCH IX. Each of GPLP, GPLLC and the ARCH Managing Directors disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any. F4: These shares are directly held by ARCH Venture Fund IX Overage, L.P. ("ARCH Overage"). ARCH Venture Partners IX Overage, L.P. ("Overage GPLP"), as the sole general partner of ARCH Overage, may be deemed to beneficially own the shares held by ARCH Overage. GPLLC, as the sole general partner of Overage GPLP, may be deemed to beneficially own the shares held by ARCH Overage. As managing directors of GPLLC, each of the ARCH Managing Directors may be deemed to beneficially own the shares held by ARCH Overage. Each of Overage GPLP, GPLLC and the ARCH Managing Directors disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any.